Placeholder

Managing Investigator Initiated Trials

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

VIEW on IITs

Investigator initiated trials (IITs) can be a valuable part of a pharmaceutical or medical-device manufacturer’s marketing claims arsenal, according to Rita Numerof, Ph.D., president, and Mark Morgan, M.S., senior business analyst, at Numerof & Associates Inc.
The two contend that IITs are relatively low cost because much of the up-front work is performed by the investigator, and the investigator normally “donates” facilities and staff to the conduct of the trial. In addition, ideas received from independent researchers can be a source of valuable new claims concepts and the perception of the independence of the research is stronger than it is for company directed trials.

Experts on this Topic
Rita E. Numerof, Ph.D., President, and Mark T. Morgan, M.S., Senior Business Analyst, at Numerof & Associates Inc. (NAI),
St. Louis. For more information, visit nai-consulting.com.

FEEDBACK